key: cord-0999312-5rsjwsgo
authors: De Luca, Giuseppe; Verdoia, Monica; Cercek, Miha; Jensen, Lisette Okkels; Vavlukis, Marija; Calmac, Lucian; Johnson, Tom; Ferrer, Gerard Rourai; Ganyukov, Vladimir; Wojakowski, Wojtek; Kinnaird, Tim; van Birgelen, Clemens; Cottin, Yves; IJsselmuiden, Alexander; Tuccillo, Bernardo; Versaci, Francesco; Royaards, Kees-Jan; Berg, Jurrien Ten; Laine, Mika; Dirksen, Maurits; Siviglia, Massimo; Casella, Gianni; Kala, Petr; Díez Gil, José Luis; Banning, Adrian; Becerra, Victor; De Simone, Ciro; Santucci, Andrea; Carrillo, Xavier; Scoccia, Alessandra; Amoroso, Giovanni; Lux, Arpad; Kovarnik, Tomas; Davlouros, Periklis; Mehilli, Julinda; Gabrielli, Gabriele; Rios, Xacobe Flores; Bakraceski, Nikola; Levesque, Sébastien; Cirrincione, Giuseppe; Guiducci, Vincenzo; Kidawa, Michał; Spedicato, Leonardo; Marinucci, Lucia; Ludman, Peter; Zilio, Filippo; Galasso, Gennaro; Fabris, Enrico; Menichelli, Maurizio; Garcia-Touchard, Arturo; Manzo, Stephane; Caiazzo, Gianluca; Moreu, Jose; Forés, Juan Sanchis; Donazzan, Luca; Vignali, Luigi; Teles, Rui; Benit, Edouard; Agostoni, Pierfrancesco; Bosa Ojeda, Francisco; Lehtola, Heidi; Camacho-Freiere, Santiago; Kraaijeveld, Adriaan; Antti, Ylitalo; Boccalatte, Marco; Deharo, Pierre; Martínez-Luengas, Iñigo Lozano; Scheller, Bruno; Alexopoulos, Dimitrios; Moreno, Raul; Kedhi, Elvin; Uccello, Giuseppe; Faurie, Benjamin; Gutierrez Barrios, Alejandro; Di Uccio, Fortunato Scotto; Wilbert, Bor; Smits, Pieter; Cortese, Giuliana; Parodi, Guido; Dudek, Dariusz
title: Impact of COVID-19 Pandemic on Mechanical Reperfusion for Patients With STEMI
date: 2020-11-17
journal: J Am Coll Cardiol
DOI: 10.1016/j.jacc.2020.09.546
sha: ba4d6cbf530d481bf260a98e886378e29439aab1
doc_id: 999312
cord_uid: 5rsjwsgo

BACKGROUND: The fear of contagion during the coronavirus disease-2019 (COVID-19) pandemic may have potentially refrained patients with ST-segment elevation myocardial infarction (STEMI) from accessing the emergency system, with subsequent impact on mortality. OBJECTIVES: The ISACS-STEMI COVID-19 registry aims to estimate the true impact of the COVID-19 pandemic on the treatment and outcome of patients with STEMI treated by primary percutaneous coronary intervention (PPCI), with identification of “at-risk” patient cohorts for failure to present or delays to treatment. METHODS: This retrospective registry was performed in European high-volume PPCI centers and assessed patients with STEMI treated with PPPCI in March/April 2019 and 2020. Main outcomes are the incidences of PPCI, delayed treatment, and in-hospital mortality. RESULTS: A total of 6,609 patients underwent PPCI in 77 centers, located in 18 countries. In 2020, during the pandemic, there was a significant reduction in PPCI as compared with 2019 (incidence rate ratio: 0.811; 95% confidence interval: 0.78 to 0.84; p < 0.0001). The heterogeneity among centers was not related to the incidence of death due to COVID-19. A significant interaction was observed for patients with arterial hypertension, who were less frequently admitted in 2020 than in 2019. Furthermore, the pandemic was associated with a significant increase in door-to-balloon and total ischemia times, which may have contributed to the higher mortality during the pandemic. CONCLUSIONS: The COVID-19 pandemic had significant impact on the treatment of patients with STEMI, with a 19% reduction in PPCI procedures, especially among patients suffering from hypertension, and a longer delay to treatment, which may have contributed to the increased mortality during the pandemic. (Primary Angioplasty for STEMI During COVID-19 Pandemic [ISACS-STEMI COVID-19] Registry; NCT04412655).

Forest plot of the incidence rate ratio on the log-scaled axis, with 95% confidence interval, across each hospital center. COVID-19 ¼ coronavirus disease-2019; PCI ¼ percutaneous coronary intervention; STEMI ¼ ST-segment elevation myocardial infarction. Furthermore, associated effects of social distancing and lockdown may have played a role, including less business-related stress, improved air quality, and a more sedentary lifestyle.

A recent small-sized report (7), including a total of 465 patients with STEMI in 54 Italian centers, showed a sizable reduction (26.5%) in STEMI procedures, more marked among women. Notably, patients with STEMI treated in 2020 had a tripled mortality rate (13.7% vs. 4.1%); however, this observation was restricted to no more than a single week, shortly after the lockdown, with fewer than 10 cases per center. An additional limitation of that study is the fact that it was not based on individual patient data, which prevents the correction for potential confounding factors.

As of now, the current study is the worldwide largest international multicenter registry in patients with STEMI who underwent mechanical reperfusion procedures, conducted in high-volume primary PCI centers. Therefore, it contributes relevant, reliable information to this controversial debate. Consistent with previous small-sized reports, we found a significant reduction in the number of patients with STEMI undergoing mechanical reperfusion; however, it was not consistent across all the centers.

The results were not related to the local or national incidence of COVID or rates of death due to COVID-19.

We found a significant interaction with the decline in procedures in patients with hypertension, whereas no interaction was observed for age, sex, and diabetes. We may certainly speculate that due to the alarming message about the interplay between COVID-19 and the renin-angiotensin-aldosterone system, specifically with the use of angiotensin- medical contact may be a consequence of both direct patient delay or emergency system-related delay, as recently described (17) . In fact, we observed in 2020 a longer ischemia time despite a higher proportion of patients who were transferred by ambulance from the community to PCI hospitals.

The longer delay to treatment contributes to the significantly higher mortality observed during this pandemic, as compared with 2019. This association persisted after correction for major differences and additionally for COVID positivity. Importantly, the COVID-positive population represented a very highrisk subgroup, with mortality exceeding 25%, confirming recent smaller reports (7, 18) . continued use of ACE inhibitors and ARBs is unlikely to be harmful in patients with COVID-19 and this may certainly reduce any fear of contagiousness for these patients (19) (20) (21) (22) . STUDY LIMITATIONS. This study is limited by its retrospective design. It was conducted during a pandemic emergency, which was challenging and expected to encounter missing data. Nevertheless, our main data analysis and conclusions are based on counts and, therefore, the overall cohort of patients was included. Furthermore, even in the analysis based on full individual patient data, this limitation and the potential risk of type II error was largely overcome by the high complete case series (>95%) and the high statistical power due to the size of the study population. Finally, even though we did not find any difference in out-of-hospital cardiac arrest, we cannot exclude that the reduction in patients with STEMI observed in 2020 may have resulted from higher rates of prehospital death due to longer delays to first medical contact, as has been described during the COVID-19 pandemic (17, 18) .

The COVID-19 pandemic had a significant impact on the treatment of patients with STEMI, resulting in a reduction in primary PCI procedures, especially among patients suffering from hypertension, and in longer delay to treatment, which may have contributed to the increased mortality during this pandemic.

Our data suggest that health authorities, supported by scientific societies, should take vigorous action to prevent patients from neglecting characteristic symptoms of an acute myocardial infarction, especially among patients who suffer from hypertension. The ISACS-STEMI COVID-19 Registry

Early transmission dynamics in Wuhan, China, of novel coronavirusinfected pneumonia

The mystery of the missing STEMIs during the COVID-19 pandemic

Reduction in ST-segment elevation cardiac catheterization laboratory activations in the United States during COVID-19 pandemic

Impact of Coronavirus Disease 2019 (COVID-19) outbreak on ST-segment-elevation myocardial infarction care in Hong Kong

Population trends in rates of percutaneous coronary revascularization for acute coronary syndromes associated with the COVID-19 outbreak

The obstacle course of reperfusion for STEMI in the COVID-19 pandemics

Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era. Soci-etàItaliana di Cardiologia and the CCU Academy investigators group

Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction: every minute of delay counts

Time-to-treatment significantly affects the extent of ST-segment resolution and myocardial blush in patients with acute myocardial infarction treated by primary angioplasty

ESC Scientific Document Group. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC)

Generalized linear models. In: Data analysis using regression and multilevel/ hierarchical models

Potential effects of coronaviruses on the cardiovascular system: a review

Systemic infections cause exaggerated local inflammation in atherosclerotic coronary arteries: clues to the triggering effect of acute infections on acute coronary syndromes

Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy

Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study

Position statement of the ESC Council on Hypertension on ACE-inhibitors and angiotensin receptor blockers

Lombardia CARe Researchers. Out-of-hospital cardiac arrest during the Covid-19 outbreak in Italy

Out-ofhospital cardiac arrest during the COVID-19 pandemic

ST-elevation myocardial infarction in patients with COVID-19: clinical and angiographic outcomes

Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study

Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors

Decreased mortality of covid-19 with renin-angiotensin-aldosterone system inhibitors therapy in patients with hypertension: a meta-analysis